Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study

Background/Aims Vedolizumab (VDZ), a gut-selective monoclonal antibody for ulcerative colitis (UC) treatment, has no established biomarkers or clinical features that predict long-term remission. Week 2 remission, a potential predictor of long-term remission, could inform maintenance treatment strate...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Taku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, Toshimitsu Fujii, Reiko Kunisaki, Tomoyoshi Shibuya, Minoru Matsuura, Ken Takeuchi, Sakiko Hiraoka, Hiroshi Yasuda, Kaoru Yokoyama, Noritaka Takatsu, Atsuo Maemoto, Toshiyuki Tahara, Keiichi Tominaga, Masaaki Shimada, Nobuaki Kuno, Mary Cavaliere, Kaori Ishiguro, Jovelle L Fernandez, Toshifumi Hibi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Korean Association for the Study of Intestinal Diseases 2026-04-01
Serie:	Intestinal Research
Soggetti:	colitis, ulcerative inflammatory bowel diseases japan vedolizumab
Accesso online:	http://irjournal.org/upload/pdf/ir-2025-00047.pdf
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!